Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PIK3CA NP_006209.2:p.H1047R

Known as: Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047R, PIK3CA p.Glu1047Arg, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047R 
A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein… Expand
National Institutes of Health

Related topics

Related topics

1 relation
PIK3CA Gene Mutation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Purpose PIK3CA, encoding for subunit p110a of PI3K, is frequently mutated in breast cancer. PIK3CA mutation was predictive for… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2020
2020
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
Dear Editor, While in Burkitt lymphoma (BL) immunochemotherapy readily induces remissions, the clinical outcomes for patients… Expand
  • figure 1
Is this relevant?
2018
2018
Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
There is currently no blood-based marker in routine use for endometrial cancer patients. Such a marker could potentially be used… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2018
2018
Abstract 3650: Use of unique molecular identifiers to gain insight about the true positive mutations in cfDNA of breast cancer patients for implementation of personalized treatment
Background: Blood analytes, as liquid biopsies, are discussed to be surrogate markers for therapy stratification, as serial… Expand
Is this relevant?
2016
2016
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas12
Mutant cancer subpopulations have the potential to derail durable patient responses to molecularly targeted cancer therapeutics… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CAH1047R in HER2/ER-positive breast cancer
PurposePhosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in human breast cancer. Furthermore, PIK3CA… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Highly sensitive detection of the PIK3CAH1047R mutation in colorectal cancer using a novel PCR-RFLP method
BackgroundThe PIK3CAH1047R mutation is considered to be a potential predictive biomarker for EGFR-targeted therapies. In this… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2015
2015
Bcl-2 together with PI3K p110α regulates cell morphology and cell migration
The signaling network of phosphatidylinositol 3-kinase (PI3K) and Akt controls cell cycle, survival, metabolism and genomic… Expand
  • figure 1
Is this relevant?
2015
2015
Abstract 1119: Subclonal structure of breast cancer subtypes determined by quantitative analyses of activating mutations
Little is known about the role of low-frequency somatic mutations in breast cancer, a cancer that is quite variable in terms of… Expand
Is this relevant?
2011
2011
Abstract 3072: Prospective study of genetic mutations in matched tumor and plasma specimens in advanced cancer patients referred to phase I trials
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: Circulating free DNA (cfDNA) represents a… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE